Date: 2011-02-17
Type of information: Licensing agreement
Compound: Veregen® ointment (made from the extract of green tea leaves - catechins)
Company: MediGene (Germany) Pierre Fabre Medicament (France)
Therapeutic area: Infectious diseases - Gynecology
Type agreement: licensing
commercialisation
distribution
Action mechanism:
Disease: External genital warts
Details: Medigene has signed a license and supply agreement with Pierre Fabre Medicament for the supply and marketing of Veregen® ointment in Mexico, Central America, Venezuela and Colombia. Pierre Fabre will be responsible for all approval procedures in the concerned countries and will promote and distribute the drug for the treatment of genital warts.
MediGene has already entered into several marketing partnerships for Veregen®, e.g. with Nycomed, Inc. for the USA, with Abbott for Germany, Austria, and Switzerland with Juste S.A.Q.F. for Spain and Portugal and Laboratoires Expanscience for France along with a number of other partners across Europe and Asia. MediGene is planning to continue this global licensing strategy.
Veregen® is currently available on the US, German, and Austrian markets. A second wave of marketing applications within the European mutual recognition procedure is planned, with Germany serving as the reference state in this process.
Financial terms: Financial details were not disclosed. MediGene is entitled to successive payments due upon conclusion of the agreement and set milestones. MediGene will supply Pierre Fabre with the drug product and obtain double-digit royalties on sales revenue.
Latest news:
